论文部分内容阅读
非胰岛素依赖型糖尿病又称2型糖尿病(NID-DM),是一种由遗传和环境因素引起的异源性疾病。在饮食治疗失败患者中,合理选择口服降糖药是治疗成败与预防并发症之关键,基本原则是在掌握药物特性的基础上结合患者临床特征及病情发展阶段而定。1 口服降糖药物1.1 磺酰脲类(刺激胰岛素分泌的药物)1956年第一代磺酰脲类甲苯磺丁脲(tolbutamide)问世,此后有氨磺丁脲(carbutamide)、妥拉磺脲(tolazamide)、氯磺丙脲(chlorpropamide)相继用于临床。1972年以后,第二代
Non-insulin-dependent diabetes, also known as type 2 diabetes mellitus (NID-DM), is a heterogeneous disease caused by genetic and environmental factors. In the diet failure patients, the rational choice of oral hypoglycemic agents is the key to the success of treatment and prevention of complications. The basic principle is to grasp the characteristics of the patients based on the clinical characteristics of patients and stage of disease may be. 1 oral glucose-lowering drugs 1.1 Sulfonylureas (drugs that stimulate insulin secretion) The first generation of sulfonylureas tolbutamide came out in 1956, followed by carbutamide, tolazamide, chlorpropamide (chlorpropamide) have been used clinically. After 1972, the second generation